Emergent BioSolutions Inc. cash flow to debt ratio of 29.82% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Emergent BioSolutions Inc.'s free cash flow has increased 337.99% from $35.80M last year to $156.80M, signaling increasing performance

Emergent BioSolutions Inc.'s debt to equity ratio is 1.10, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Emergent BioSolutions Inc.'s debt has decreased relative to shareholder equity from 1.40 last year to 1.10 today, signaling strengthened financials

Emergent BioSolutions Inc. has a net debt to EBITDA ratio of 1.53x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Emergent BioSolutions Inc.'s interest coverage ratio is 1.28, which means that the company struggles to meet interest obligations, signaling financial risk.

Emergent BioSolutions Inc.'s profit margin has increased (-93.04%) in the last year from -18.26% to -1.27%, signaling increasing performance

Emergent BioSolutions Inc.'s short-term assets of $662.50M exceed its short-term liabilities of $132.20M

Emergent BioSolutions Inc.'s return on assets of -0.65% is lower than the 5.00% threshold, indicating inefficient asset utilization

Emergent BioSolutions Inc.'s return on equity of -1.59%, is lower than 15.00%, indicating bad performance

Emergent BioSolutions Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Emergent BioSolutions Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Emergent BioSolutions Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Emergent BioSolutions Inc. has a free cash flow yield of 40.52%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Emergent BioSolutions Inc.'s yearly earnings has increased -127.60% since last year from $-190.60M to $52.60M, signaling increasing performance

Emergent BioSolutions Inc.'s yearly revenue has decreased -26.71% since last year from $1.01G to $742.90M, signaling decreasing performance

ROIC -14.93% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Emergent BioSolutions Inc.'s 3-year revenue CAGR of -12.72% is negative, indicating declining revenue over the past 3 years

Emergent BioSolutions Inc. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance

Emergent BioSolutions Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Emergent BioSolutions Inc. is undervalued relative to its fair value price of 9.50 based on Discounted Cash Flow model

Emergent BioSolutions Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Emergent BioSolutions Inc. is undervalued relative to its fair value price of 21.11 based on EBITDA multiple model

Emergent BioSolutions Inc. has an EV/EBITDA ratio of 3.14x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Emergent BioSolutions Inc. is overvalued relative to its fair value price of -9.16 based on Earnings Fair Value model

Emergent BioSolutions Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Emergent BioSolutions Inc. has a price-to-book ratio of 0.74x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Emergent BioSolutions Inc. has a price-to-sales ratio of 0.58x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue